| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 6.35M | 22.38M | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | 2.53% | -1% | - | - | - |
| Cost of Goods Sold | 582K | 1.68M | 34.22M | 46.55M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | 5.39% | 2.08% | - | - | - | - |
| Gross Profit | -582K | -1.68M | -27.87M | -24.18M | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | -4.39% | -1.08% | - | - | - | - |
| Gross Profit Growth % | - | -1.88% | -15.62% | 0.13% | 1% | - | - | - |
| Operating Expenses | 15.55M | 23.2M | 9.61M | 17.05M | 70.77M | 75.91M | 67.64M | 59.75M |
| OpEx % of Revenue | - | - | 1.51% | 0.76% | - | - | - | - |
| Selling, General & Admin | 2.6M | 3.41M | 9.61M | 17.05M | 20.57M | 21.71M | 19.71M | 15.72M |
| SG&A % of Revenue | - | - | 1.51% | 0.76% | - | - | - | - |
| Research & Development | 12.95M | 19.79M | 34.22M | 46.55M | 50.19M | 54.2M | 47.93M | 41.49M |
| R&D % of Revenue | - | - | 5.39% | 2.08% | - | - | - | - |
| Other Operating Expenses | 80K | 397K | -34.22M | -46.55M | 0 | 0 | 0 | 2.54M |
| Operating Income | -15.55M | -23.2M | -37.48M | -41.23M | -70.77M | -75.91M | -67.64M | -59.75M |
| Operating Margin % | - | - | -5.91% | -1.84% | - | - | - | - |
| Operating Income Growth % | - | -0.49% | -0.62% | -0.1% | -0.72% | -0.07% | 0.11% | 0.12% |
| EBITDA | -14.97M | -21.52M | -34.79M | -37.81M | -66.59M | -71.78M | -63.95M | -56.88M |
| EBITDA Margin % | - | - | -5.48% | -1.69% | - | - | - | - |
| EBITDA Growth % | - | -0.44% | -0.62% | -0.09% | -0.76% | -0.08% | 0.11% | 0.11% |
| D&A (Non-Cash Add-back) | 582K | 1.68M | 2.69M | 3.41M | 4.18M | 4.12M | 3.68M | 2.87M |
| EBIT | -15.44M | -22.77M | -37.48M | -41.23M | -70.77M | -75.91M | -67.64M | -57.21M |
| Net Interest Income | 0 | 0 | -205.25K | -178.45K | -75.68K | 1.17M | 0 | 0 |
| Interest Income | 0 | 0 | 3.75K | 4.55K | 1.32K | 1.17M | 0 | 0 |
| Interest Expense | 0 | 0 | 209K | 183K | 77K | 0 | 0 | 0 |
| Other Income/Expense | 80K | 397K | 3.75M | 4.62M | 1.38M | 1.18M | 4.91M | 4.09M |
| Pretax Income | -15.47M | -22.8M | -33.74M | -36.6M | -69.39M | -74.73M | -62.72M | -55.65M |
| Pretax Margin % | - | - | -5.32% | -1.64% | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -15.47M | -22.8M | -33.74M | -36.6M | -69.39M | -74.73M | -62.72M | -55.65M |
| Net Margin % | - | - | -5.32% | -1.64% | - | - | - | - |
| Net Income Growth % | - | -0.47% | -0.48% | -0.08% | -0.9% | -0.08% | 0.16% | 0.11% |
| Net Income (Continuing) | -15.47M | -22.8M | -33.74M | -36.6M | -69.39M | -74.73M | -62.72M | -55.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -8.17 | -12.04 | -25.79 | -15.95 | -30.15 | -32.32 | -27.04 | -23.88 |
| EPS Growth % | - | -0.47% | -1.14% | 0.38% | -0.89% | -0.07% | 0.16% | 0.12% |
| EPS (Basic) | -8.17 | -12.04 | -25.79 | -15.95 | -30.15 | -32.32 | -27.04 | -23.88 |
| Diluted Shares Outstanding | 1.89M | 1.89M | 1.31M | 2.29M | 2.3M | 2.31M | 2.32M | 2.33M |
| Basic Shares Outstanding | 1.89M | 1.89M | 1.31M | 2.29M | 2.3M | 2.31M | 2.32M | 2.33M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 9.42M | 135.78M | 340M | 287.98M | 227.82M | 163.98M | 112.72M | 71.81M |
| Cash & Short-Term Investments | 8.43M | 135.17M | 334.61M | 283.45M | 219.59M | 159.91M | 108.3M | 68.62M |
| Cash Only | 8.43M | 135.17M | 34.09M | 32.77M | 12.34M | 26.63M | 13.08M | 27.73M |
| Short-Term Investments | 0 | 0 | 300.51M | 250.68M | 207.25M | 133.28M | 95.22M | 40.89M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 700K | 800K | 300K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | -700K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 860K | 460K | 1.71M | 1.71M | 39K | 4.07M | 3.63M | 2.89M |
| Total Non-Current Assets | 10.05M | 11.84M | 16.17M | 18.67M | 14.57M | 20.18M | 15.31M | 9.05M |
| Property, Plant & Equipment | 10.02M | 11.41M | 12.09M | 15.81M | 13.99M | 16.91M | 13.43M | 8.72M |
| Fixed Asset Turnover | - | - | 0.52x | 1.42x | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 3.33M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 26K | 436K | 750K | 2.86M | 577K | 1.73M | 1.88M | 332K |
| Total Assets | 19.47M | 147.63M | 356.17M | 306.64M | 242.39M | 184.16M | 128.04M | 80.86M |
| Asset Turnover | - | - | 0.02x | 0.07x | - | - | - | - |
| Asset Growth % | - | 6.58% | 1.41% | -0.14% | -0.21% | -0.24% | -0.3% | -0.37% |
| Total Current Liabilities | 3.12M | 10.3M | 15.04M | 10.32M | 6.61M | 9.13M | 6.88M | 9.57M |
| Accounts Payable | 1.14M | 2.48M | 1.86M | 3.9M | 1.94M | 4.27M | 2.33M | 5.35M |
| Days Payables Outstanding | 715.58 | 540.43 | 19.85 | 30.59 | - | - | - | - |
| Short-Term Debt | 400K | 387K | 1.67M | 1.67M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | -504K | 1000K | 1000K | 130K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 19K | 28K | 234K | 13K | 2.92M | 2.7M | 113K | 1.67M |
| Current Ratio | 3.02x | 13.19x | 22.60x | 27.89x | 34.48x | 17.97x | 16.38x | 7.50x |
| Quick Ratio | 3.02x | 13.19x | 22.60x | 27.89x | 34.48x | 18.04x | 16.38x | 7.50x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 40.76M | 184.27M | 19.64M | 2.6M | 2.39M | 7.5M | 6.73M | 5.81M |
| Long-Term Debt | 460K | 73K | 3.33M | 1.81M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 6.61M | 5.95M | 5.15M |
| Deferred Tax Liabilities | 0 | 0 | 0 | -15.95M | 0 | 1.54M | 0 | 0 |
| Other Non-Current Liabilities | 40.3M | 162.47M | 359K | 792K | 2.39M | 899K | 785K | 661K |
| Total Liabilities | 43.88M | 194.57M | 34.68M | 12.92M | 9M | 16.63M | 13.62M | 15.39M |
| Total Debt | 964K | 587K | 5.13M | 3.47M | 0 | 7.12M | 6.61M | 5.95M |
| Net Debt | -7.46M | -134.59M | -28.96M | -29.3M | -12.34M | -19.51M | -6.48M | -21.78M |
| Debt / Equity | - | - | 0.02x | 0.01x | - | 0.04x | 0.06x | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -179.34x | -225.27x | -919.03x | - | - | - |
| Total Equity | -24.41M | -46.94M | 321.48M | 293.72M | 233.39M | 167.53M | 114.42M | 65.47M |
| Equity Growth % | - | -0.92% | 7.85% | -0.09% | -0.21% | -0.28% | -0.32% | -0.43% |
| Book Value per Share | -12.90 | -24.80 | 245.79 | 128.02 | 101.41 | 72.46 | 49.33 | 28.09 |
| Total Shareholders' Equity | -24.41M | -46.94M | 321.48M | 293.72M | 233.39M | 167.53M | 114.42M | 65.47M |
| Common Stock | 11K | 11K | 27K | 28K | 28K | 28K | 28K | 28K |
| Retained Earnings | -24.5M | -47.3M | -81.03M | -117.64M | -187.03M | -261.76M | -324.48M | -380.14M |
| Treasury Stock | -75K | -332K | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -792K | -2.47M | -38K | 779K | -663K | -1.49M | -222K | 4K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.51M | 7.99M | -35.62M | -44.95M | -57.24M | -53.89M | -52.97M | -40.8M |
| Operating CF Margin % | - | - | -5.61% | -2.01% | - | - | - | - |
| Operating CF Growth % | - | 1.64% | -5.46% | -0.26% | -0.27% | 0.06% | 0.02% | 0.23% |
| Net Income | -15.47M | -22.8M | -33.74M | -36.6M | -69.39M | -74.73M | -62.72M | -55.65M |
| Depreciation & Amortization | 582K | 1.68M | 2.69M | 3.41M | 7.2M | 4.12M | 3.68M | 2.87M |
| Stock-Based Compensation | 75K | 263K | 1.89M | 7.91M | 10.29M | 9.51M | 8.19M | 6.33M |
| Deferred Taxes | 0 | 0 | -7.26M | -12.7M | -23.74M | 0 | 0 | 0 |
| Other Non-Cash Items | 1.24M | 3.21M | 7.26M | 12.7M | 23.74M | 3.49M | -183K | 1.12M |
| Working Capital Changes | 2.3M | 28.85M | -6.46M | -19.68M | -5.34M | 3.73M | -1.94M | 4.53M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 767K | 1.34M | -622K | 2.04M | -1.96M | 2.33M | -1.94M | 3.02M |
| Cash from Investing | -8.65M | -3.06M | -303.92M | 43.52M | 36.6M | 67.98M | 39.27M | 55.31M |
| Capital Expenditures | -8.65M | -3.06M | -3.37M | -7.13M | -2.36M | -2.12M | -820K | -474K |
| CapEx % of Revenue | - | - | 0.53% | 0.32% | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 50.66K | 38.96K | 70.09K | 0 | 0 |
| Cash from Financing | 24.86M | 121.42M | 243.04M | -1.42M | -3.27M | 200K | 154K | 144K |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 0 | -410K | 0 | 0 | 0 | 0 | 0 | 105K |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -21.17M | 4.93M | -38.99M | -52.09M | -59.6M | -56M | -53.79M | -41.28M |
| FCF Margin % | - | - | -6.14% | -2.33% | - | - | - | - |
| FCF Growth % | - | 1.23% | -8.91% | -0.34% | -0.14% | 0.06% | 0.04% | 0.23% |
| FCF per Share | -11.18 | 2.60 | -29.81 | -22.70 | -25.90 | -24.22 | -23.19 | -17.71 |
| FCF Conversion (FCF/Net Income) | 0.81x | -0.35x | 1.06x | 1.23x | 0.82x | 0.72x | 0.84x | 0.73x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -24.58% | -11.9% | -26.33% | -37.28% | -44.49% | -61.87% |
| Return on Invested Capital (ROIC) | - | - | -50.65% | -11.1% | -21.86% | -30.85% | -39.64% | -59.1% |
| Gross Margin | - | - | -439.09% | -108.03% | - | - | - | - |
| Net Margin | - | - | -531.54% | -163.57% | - | - | - | - |
| Debt / Equity | - | - | 0.02x | 0.01x | - | 0.04x | 0.06x | 0.09x |
| Interest Coverage | - | - | -179.34x | -225.27x | -919.03x | - | - | - |
| FCF Conversion | 0.81x | -0.35x | 1.06x | 1.23x | 0.82x | 0.72x | 0.84x | 0.73x |
| Revenue Growth | - | - | - | 252.58% | -100% | - | - | - |
NextCure, Inc. (NXTC) grew revenue by 0.0% over the past year. Growth has been modest.
NextCure, Inc. (NXTC) reported a net loss of $58.0M for fiscal year 2024.
NextCure, Inc. (NXTC) has a return on equity (ROE) of -61.9%. Negative ROE indicates the company is unprofitable.
NextCure, Inc. (NXTC) had negative free cash flow of $48.9M in fiscal year 2024, likely due to heavy capital investments.